Introduction {#s1}
============

A persistent infection with high risk human papillomaviruses (HR-HPV) in particular HPV16 and 18 is recognized as the highest risk factor for the development of cervical cancer [@pone.0039632-Munoz1]. Most HR-HPV infections are either latent or permissive. Latent infections are ill defined but it is assumed that the viral genome is maintained as an episome in the basal and parabasal cells of the epithelium without inducing obvious phenotypic alterations in the host cell. Virus replication in terms of virion production is confined to terminally differentiated cells of the intermediate and superficial epithelial layers and results from a switch of a latent to a permissive phase or directly from an acute infection. Normally HR-HPV infections are self-limited and resolve within several months. However, in an estimated 10% of cases a transforming type of HPV infection evolves. This transformation process is characterized by the deregulation of viral oncogenes E6 and E7 in cycling cells which ultimately results in chromosomal instability and the accumulation of mutations. The underlying mechanisms for deregulation are manifold. Integration of the HPV genome is a characteristic step in cervical carcinogenesis and its appearance correlates with the progression of precancerous lesions (CIN2/3) to invasive carcinoma [@pone.0039632-Durst1], [@pone.0039632-Wentzensen1], [@pone.0039632-Pett1], [@pone.0039632-Kalantari1], [@pone.0039632-Klaes1]. However, integration is not mandatory in this process and was shown to be HPV-type dependent. Vinokurova and colleagues observed that HPV16, 18 and 45 were substantially more often present in an integrated state compared with HPV types 31 and 33 [@pone.0039632-Vinokurova1]. Interestingly the highest carcinogenic potential is ascribed to HPV16 and HPV18 [@pone.0039632-Khan1].

The loss of the viral E2 gene is a common consequence of HPV integration. This event may lead to an elevated expression of the oncogenes E6 and E7 due to the fact that E2 is no longer able to repress the expression of the viral oncogenes *in trans* [@pone.0039632-Romanczuk1], [@pone.0039632-Baker1]. However, of note is that in a recent analysis of biopsy material no correlation between the expression levels of viral oncogene transcripts and the physical state of the viral genome was found [@pone.0039632-Hafner1]. Since the transcriptionally active viral integration sites thus far analysed in CIN2/3 or cervical carcinomas represent the end point of a clonal selection process the most pragmatic interpretation of the data is that integration ensures a constitutive expression of the viral oncogenes at a level required to maintain the transformed state of the cell. More recently several investigators have also focussed on the impact integration may have on the host genome. A systematic analysis of the genome structure at the integration locus has revealed frequent genomic structural alterations at the HPV insertion sites in cervical carcinoma [@pone.0039632-Peter1]. Two further publications provide evidence for a complete functional loss of the tumor suppressor genes, *ZBTB7C* and *CASZ1*, respectively. In both cases gene expression is prevented due to insertional mutagenesis in combination with loss of heterozygosity [@pone.0039632-Reuter1], [@pone.0039632-Schmitz1]. Although such constellations are likely to be rare events it becomes increasingly more evident that HPV integration does not occur entirely at random. In a previous study we could show that the majority of viral-cellular fusion transcripts in cervical carcinomas co-transcribe cellular sequences of known or predicted genes. Indeed, 17 of 74 (23%) of the integration sites were located within the cytogenetic bands 4q13.3, 8q24.21, 13q22.1, and 17q21.2, in clusters ranging from 86 to 900 kb. The integration hotspots 8q24.21 and 13q22.1 are close to adjacent fragile sites. Of interest is that integration within the MYC locus on 8q24.21 is strongly correlated with high levels of *MYC* expression [@pone.0039632-Ferber1], [@pone.0039632-Popescu1], [@pone.0039632-Peter2] implying *cis* regulatory effects being exerted by the viral genome.

The phenomenon of non-random integration of HPV DNA is intriguing and may not just be a question of chromatin accessibility in transcriptionally active regions or fragile sites which are prone to double strand breaks [@pone.0039632-Koopman1], [@pone.0039632-Thorland1], [@pone.0039632-Ziegert1]. For a better understanding of the role and mechanisms of virus integration in cervical carcinogenesis it is necessary to gather more data for comparative purposes. Accordingly, we have analysed the viral-cellular fusion transcripts of 34 HPV16 positive and 13 HPV18 positive cervical carcinomas. On the basis of this new data the previously defined hotspots for integration could be confirmed and extended upon. There is also mounting evidence that numerous genes are affected more than once by integration.

Results {#s2}
=======

In 47 of 87 HPV16 or HPV18 positive tumors analysed viral-cellular fusion transcripts could be amplified. Fusion transcripts were detected more frequently in HPV18 positive tumors (72%) than in HPV16 positive tumors (49%). The remaining tumors contained either only episomal viral genomes or integrated HPV DNA which is transcriptionally silent. The cellular sequences of the fusion transcripts were characterized using the NCBI human megaBlast tool. To identify expressed sequence tags and predicted genes all additional cellular sequences were analysed using the UCSC blat database.

Chromosomal Assignment of the Fusion Transcripts {#s2a}
------------------------------------------------

In total, 23 fusion transcripts contained sequences of known genes and 23 contained sequences of predicted genes and ESTs. In one case the cellular sequence did not match any database entries. The viral cellular fusion transcripts could be assigned to all chromosomes, except for chromosome 11, 14, 16, 18 and 20 and are summarized in [table 1](#pone-0039632-t001){ref-type="table"}. In a previous study we had already described that some regions are more frequently affected by integration than other parts of the genome [@pone.0039632-Kraus1]. For three of these hotspots we have now found additional integration events: The regions 8q24.21 and 13q22.1 were affected twice and region 4q13.3 was affected once. Moreover, three fusion transcripts were mapped to a 600 kb region in the chromosomal cytogenetic band 3q28 and thus represent a new hotspot for HPV integration. [Figure 1](#pone-0039632-g001){ref-type="fig"} includes the data from Kraus and colleagues and depicts all five hotspots, their size and the vicinity to related fragile sites and miRNAs.

![Chromosomal hotspots for HPV integration.\
Depicted are integration sites located within the cytogenetic bands 3q28 (A), 4q13.3 (B), 8q24.21 (C), 13q22.1 (D) and 17q21.2 (E). Light blue arrows: genes affected by HPV integration; red arrows: HPV fusion transcripts described in this work; grey arrows: HPV fusion transcripts described by Kraus et al. 2008; green arrows: fragile site; dark blue arrows: microRNAs.](pone.0039632.g001){#pone-0039632-g001}
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###### Summary of all viral-cellular fusion transcripts analysed.

![](pone.0039632.t001){#pone-0039632-t001-1}

  Sample    HPV        Chr. match                       Accession Code                                                                       Gene Name                                                       Spliced or fused to    Orientation   Fragile site[1](#nt101){ref-type="table-fn"}                                                                                                                            miRNAs                                                                                                                            
  -------- ----- ---------------------- ----------------------------------------------- ------------------------------------------------------------------------------------------------------------------- ---------------------- ------------- ---------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------
  T3726     16          1p36.21                            C1orf196                                                             Chromosome 1 open reading frame 196                                                  n.a.               AS                        FRA1A (1p36)                                                                                                                                              \-                                                                                                                              
  T6248     18          1p36.22                           intergenic                                                                                                                                                  \-                                          FRA1A (1p36)                                                                                                  MIR34a: 9,211,727--9,211,836MIR5697: 10,027,439--10,027,516MIR1273d: 10,287,776--10,287,861                                                                                    1p36.22
  T2319     16          1p36.22                              CASZ1                                                                     Castor zinc finger 1                                                        exon 21               S                        FRA1A (1p36)                                                                                                                                                                                                                                                                              
  T4347     16           1q42.3                    BC016972 ( = uc001hwk.1)                                                                                                                                          n.a.               AS                FRA1H (1q42.1) 5 Mb distance                                                                                      MIR4753: 235,353,349--235,353,431MIR1537: 236,016,300--236,016,360MIR4428: 237,634,419--237,634,491                                                                                 1q42.3
  T1900     18           1q42.3                              LYST                                                                 Lysosomal trafficking regulator                                                    n.a.               AS                FRA1H (1q42.1) 5 Mb distance                                                                                                                                                                                                                                                                      
  T5066     16           2p16.3                              NRXN1                                                                          Neurexin 1                                                               n.a.               AS                FRA2D (1p16.2) 1 Mb distance                                                                                                                                      \-                                                                                                                              
  T892      16           2p23.2                              GPN1                                                                        GPN-loop GTPase 1                                                           n.a.               AS                             \-                                                                                                                     MIR1301: 25,551,509--25,551,590MIR4263: 28,219,234--28,219,316                                                                                                 2p23.32p23.2
  T1875     16    2q33.1/2q32.3/2q33.1               ORC2/intergenic/BZW1                                   Origin recognition complex, subunit 2/basic leucine zipper and W2 domains 1                          n.a.-exon 1           AS-S                            \-                                                                                                                                                   \-                                                                                                                              
  T2882     16           2q22.3                      N-SCAN: chr2.3.305.a                                                                                                                                        intron 6--7             S                     *FRA2K (2*q*22.3)*                                                                                                                                                                                                                                                                           
  T3562     18           2q22.3                      N-SCAN: chr2.3.305.a                                                                                                                                            n.a.               AS                     *FRA2K (2*q*22.3)*                                                                                                                                                                                                                                                                           
  T3987     16            2q34                               ERBB4                                               V-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian)                                    n.a.              ASAS                FRA2I (2q33) 3 Mb distance                                                                                                       MIR548f2: 213,290,987--213,291,084MIR4776: 213,790,981--213,791,060                                                                                                  2q34
  T5234     16          3p21.31                              USP4                                                         Ubiquitin specific peptidase 4 (proto-oncogene)                                       intron 15--16            S                             \-                                                        MIR425: 49,057,581--49,057,667 MIR191: 49,058,051--49,058,142MIR4271: 49,311,553--49,311,619MIR5193: 49,843,570--49,843,678MIR566: 50,210,759--50,210,852MIR4748: 50,712,511--50,712,594                                      3p21.31
  T18       16           3q26.2                              MDS1                                                                   MDS1 and EVI1 complex locus                                                      n.a.               AS                             \-                                                                                                                   MIR551b: 168,269,642--168,269,737 MIR569: 170,824,453--170,824,548                                                                                                  3q26.2
  T4335     16            3q28                               TP63                                                                        Tumor protein p63                                                           n.a.               AS                 FRA3C (3q27) 2 Mb distance                                                                                                        MIR28: 188,406,569--188,406,654 MIR944: 189,547,711--189,547,798                                                                                                    3q28
  T4426     16            3q28                          Gencode: CLDN16                                                                                                                                              n.a.               AS                 FRA3C (3q27) 2 Mb distance                                                                                                                                                                                                                                                                       
  T2107     16            3q28                              LEPREL1                                                                       Leprecan-like 1                                                    exon 15intron 14--15       SS                 FRA3C (3q27) 2 Mb distance                                                                                                                                                                                                                                                                       
  T458      16            4p14                       Genscan: NT_006238.1                                                                                                                                       intron 14--15            S                 FRA4D (4p15) 5 Mb distance                                                                                                         MIR5591: 39,413,530--39,413,594MIR4802: 40,504,057--40,504,136                                                                                                     4p14
  T3966     16           4q13.3                      Genscan: NT_006216.30                                                                                                                                           n.a.               AS                             \-                                                                                                                                                   \-                                                                                                                              
  T4024     16            4q23                         C4orf17/LOC84103                                                         Chromosome 4 open reading frame 17                                                   n.a.               AS                             \-                                                                                                                                     MIR3684: 99,918,538--99,918,611                                                                                                                    4q23
  T106      16          4q31.21                       Genscan: chr4_71.7                                                                                                                                             n.a.               AS               FRA4C (4q31.1) 200 Kb distance                                                                                                                                     \-                                                                                                                              
  T4034     18           5q13.2                              RGNEF                                                              Guanine nucleotide exchange factor                                                 exon 37               S                             \-                                                                                                                                                   \-                                                                                                                              
  T3377     18           5q23.1                            BC036311                                                                                                                                                 exon 3               S                             \-                                                                                                                  MIR1244-2: 118,310,281--118,310,365MIR5706: 118,490,332--118,490,411                                                                                                 5q23.1
  T3576     16           6p21.1                      N-SCAN: chr6.1.607.a                                                                                                                                           exon 2               S                             \-                                                                                                      MIR4647: 44,221,943--44,222,022MIR4642: 44,403,378--44,403,459MIR586: 45,165,411--45,165,507                                                                                     6p21.1
  T2128     16           6p25.1           Genscan: chr6_3.24N-SCAN EST: chr6.7.003.a                                                                                                                           intron 1--2n.a.          SAS                      FRA6B (6p25.1)                                                                                                                                             \-                                                                                                                              
  T4502     18            7q34                               UBN2                                                                          Ubinuclein 2                                                            exon 13               S                             \-                                                                                                                                    MIR4468: 137,808,504--137,808,567                                                                                                                   7q33
  T5189     16          8q24.21                            LOC727677                                                                                                                                                 n.a.               AS             FRA8C/*FRA8E* 8q24.1 1 Mb distance                                                MIR1205: 128,972,879--128,972,941 MIR1206: 129,021,144--129,021,202 MIR1207: 129,061,398--129,061,484 MIR1204: 128,808,208--128,808,274 MIR1208: 129,162,362--129,162,434                                             8q24.21
  T6697     18          8q24.21                            LOC727677                                                                                                                                                exon 6               S             FRA8C/*FRA8E* 8q24.1 1 Mb distance                                                                                                                                                                                                                                                                   
  T1509     16           9p13.3                              UBAP2                                                                Ubiquitin associated protein 2                                                     n.a.               AS                             \-                                                                                                                                                   \-                                                                                                                              
  T5254     18           9p21.3                       N-SCAN: chr9.132.a                                                                                                                                             n.a.               AS                     FRA9C/FRA9D (9p21)                                                                                MIR491: 20,716,104--20,716,187MIR31: 21,512,114--21,512,184MIR4474: 20,502,263--20,502,340MIR4473: 20,411,146--20,411,236                                                                      9p21.3
  T4601     16            9p23             N-Scan: chr9.068.aGenscan: NT_008413.226                                                                                                                            intron 8--9n.a.          SAS                            \-                                                                                                                                                   \-                                                                                                                              
  T186e     16          9q21.32                     Genscan: NT_023935.256                                                                                                                                       intron 2--3             S                             \-                                                                                                                                     MIR7-1: 86,584,663--86,584,772                                                                                                                   9q21.32
  T3256     16          10q24.2                      Geneid: chr10_1119.1                                                                                                                                        intron 1--2             S                    *FRA10A (10*q*24.2)*                                                                                                                           MIR608: 102,734,742--102,734,841                                                                                                                  10q24.31
  T1820     16          12q21.33                         EST: AA296845                                                                                                                                               n.a.               AS                      FRA12B (12q21.3)                                                                                                                                            \-                                                                                                                              
  T4046     16          13q22.1                       Geneid: chr13_451.1                                                                                                                                            n.a.               AS               FRA13B (13q21) 800 Kb distance                                                                                                                                     \-                                                                                                                              
  T3970     18          13q22.1                      Genscan: chr13_27.49                                                                                                                                            n.a.               AS                FRA13B (13q21) 1 Mb distance                                                                                                                                      \-                                                                                                                              
  T182e     16          15q22.1                              LIPC                                                                         hepatic Lipase                                                            exon 5               S                       FRA15A (15q22)                                                                                                                               MIR2116: 59,463,382--59,463,461                                                                                                                  15q22.2
  T1907     16          15q22.1                              LIPC                                                                         hepatic Lipase                                                            exon 9               S                       FRA15A (15q22)                                                                                                                                                                                                                                                                             
  T2317     16          15q26.1                             SEMA4B                       Sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4 B           n.a.               AS                             \-                                        MIR7-2: 89,155,056--89,155,165MIR3529: 89,155,078--89,155,155MIR9-3: 89,911,248--89,911,337 MIR1179: 89,151,338--89,151,428MIR5094: 90,393,869--90,393,953MIR5009: 90,427,163--90,427,262MIR3174: 90,549,987--90,550,073                      15q26.1
  T3427     16          17p11.2          Ensemble: ENST00000431878Genscan: chr17_10.56                                                                                                                             exonn.a.             SAS            *FRA17A (17*q*23.1)* 4 Mb distance                                                                                                                     MIR1180: 19,247,819--19,247,887                                                                                                                  17p11.2
  T4112     18          17p13.1                              FXR2                                                        Fragile X mental retardation, autosomal homolog 2                                          exon 8               S             *FRA17A (17*q*23.1)* 3 Mb distance                                                                                          MIR497: 6,921,230--6,921,341MIR324: 7,126,616--7,126,698MIR195: 6,920,934--6,921,020                                                                                        17p13.1
  T2723     18          17q23.1                             TMEM49                                                                   Transmembrane protein 49                                                      exon 12               S                      FRA17B (17q23.1)                                                                 MIR454: 57,215,119--57,215,233 MIR301a: 57,228,497--57,228,582MIR4729: 57,443,444--57,443,515MIR21: 57,918,627--57,918,698MIR4737: 58,120,386--58,120,466                                                      17q22
  T3231     18          17q23.1                             TMEM49                                                                   Transmembrane protein 49                                                      exon 12               S                      FRA17B (17q23.1)                                                                                                                                                                                                                                                                               17q23.1
  T2967     16          19p13.11                            GATAD2A                                                            GATA zinc finger domain containing 2A                                                exon 9               S                      *FRA19B (19p13)*                                                                                            MIR640: 19,545,872--19,545,967 MIR1270--1: 20,510,081--20,510,163MIR1270--2: 20,579,240--20,579,322                                                                                19p13.11
  T4292     16          19p13.12                            NANOS3                                                                 Nanos homolog 3 (Drosophila)                                                     exon 3               S                      *FRA19B (19p13)*                 MIR693: 14,640,355--14,640,452 MIR181C: 13,985,513--13,985,622 MIR181D: 13,985,689--13,985,825 MIR23a: 13,947,401--13,947,473 MIR27a: 13,947,254--13,947,331MIR24-2: 13,947,101--13,947,173MIR5684: 12,897,942--12,898,006MIR5695: 13,031,134--13,031,218     19p13.12
  T4995     18          19p13.3                              CNN2                                                                           Calponin 2                                                              exon 7               S                      *FRA19B (19p13)*                                                                        MIR4745: 804,940--805,001MIR3187: 813,584--813,653MIR1227: 2,234,061--2,234,148 MIR1909: 1,816,158--1,816,237MIR4321: 2,250,638--2,250,717                                                             19p13.3
  T3840     16          21q11.2                          EST: DR423233                                                                                                                                               n.a.               AS                             \-                                                                                                    MIR99a: 17,911,409--17,911,489 MIRlet7c: 17,912,148--17,912,231 MIR125B2: 17,962,557--17,962,645                                                                                  21q21.1
  T4417     16           Xp21.3                               ARX                                                                   Aristaless related homeobox                                                      n.a.               AS                             \-                                                                                                                                                   \-                                                                                                                              

Common and rare fragile sites located at a distance of up to 5 Mb adjacent to the integration locus. Rare fragile sites are shown in italics.

n.a.: not applicable, because fusion transcript is in antisense orientation.

Association with Fragile Sites and miRNAs {#s2b}
-----------------------------------------

Of the 47 integration loci identified, 10 (21%) occurred within a common fragile site (CFS) and 6 (13%) in rare fragile sites. Moreover, in 15 (32%) cases the integration sites were flanking fragile sites at a distance of 200 kb up 5 Mb. Another 16 integration sites were not associated with fragile sites. Moreover, 32 integration sites were located within a distance of 3 Mb to miRNAs ([table 1](#pone-0039632-t001){ref-type="table"}).

Orientation of ORFs within Fusion Tanscripts {#s2c}
--------------------------------------------

Twenty-three of 47 fusion transcripts contained sequences of known genes. In 12 cases the host gene was orientated in the direction of viral promoter i.e. both viral and human sequences were in sense orientation. In almost all of these tumors, the viral sequence was spliced to a cellular exon sequence (11 of 12 events). 23 fusion transcripts contained predicted gene sequences and 8 were integrated in sense orientation. In 3 cases the orientation could not be determined because of inconsistency among the databases used ([table 1](#pone-0039632-t001){ref-type="table"}).

Identical Genes are Affected by Integration in different Tumors {#s2d}
---------------------------------------------------------------

By compiling the data of this study and published data five genes and four predicted genes could be identified which were affected at least twice in independent tumors ([Table 2](#pone-0039632-t002){ref-type="table"}). Four of these genes are located in the hotspots 3q28 (*LEPREL1* and *TP63*), 8q24.1 (*LOC727677*) and 13q22.1 (*BG182794*). The other genes are located elsewhere in the genome. Whereas the genes *Chr2.3.305.a*, *LEPREL1*, *NT_008046.7*, and *LIPC* were affected twice by integration, *TP63* was affected three times, *LRP1B*, *LOC727677* and *BG182794* four times and *TMEM49* even six times.

10.1371/journal.pone.0039632.t002

###### Genes affected by HPV integration at least twice in individual tumors.

![](pone.0039632.t002){#pone-0039632-t002-2}

  Name                                     HPV   Pathology    Locus        Gene       Gene size (nt)   Spliced to[‡](#nt103){ref-type="table-fn"}   Orientation   Detection method    Reference^†^
  --------------------------------------- ----- ----------- --------- -------------- ---------------- -------------------------------------------- ------------- ------------------ -----------------
  D3918                                    18      CxCa      2q22.1       LRP1B         1.900.274                         n.a.                          AS              Apot           Kraus 2008
  T654                                     45      CxCa      2q22.1       LRP1B                                           n.a.                          AS              Apot           Kraus 2008
  T19                                      16      CxCa      2q22.1       LRP1B                                         exon 28                          S              Apot          Ziegert 2003
  HK9                                      18      CxCa      2q22.1       LRP1B                                       intron 41^2^                     n.s.       Restriction PCR      Ferber 2003
  T2882                                    16      CxCa      2q22.3    chr2.3.305.a      567.027                      intron 6--7                        S              Apot        
  T3562                                    18      CxCa      2q22.3    chr2.3.305.a                                       n.a.                          AS              Apot        
  D3829                                    45      CxCa       3q28       LEPREL1         164.391                         exon 9                          S              Apot           Kraus 2008
  T2107[1](#nt104){ref-type="table-fn"}    16      CxCa       3q28       LEPREL1                                        exon 15                          S              Apot        
                                                                         LEPREL1                                     intron 14--15                       S              Apot        
  T4335                                    16      CxCa       3q28         TP63          265.852                          n.a.                          AS              Apot        
  Clone C5                                 16    cell line    3q28       TP63^3^                                       intron^2^                       n.s.       Restriction PCR       Dall 2008
  int4                                     16      VINX       3q28         TP63                                           n.s.                         n.s.             Apot         Wentzensen 2002
  D4045                                    18      CxCa      8q21.2    NT_008046.7      5.247.020                       intron 2                         S              Apot           Kraus 2008
  D4056                                    45      CxCa      8q21.2    NT_008046.7                                      intron 2                         S              Apot           Kraus 2008
  D3464                                    18      CxCa      8q24.21   LOC727677^4^      192.322                         exon 6                          S              Apot           Kraus 2008
  D3631                                    45      CxCa      8q24.21   LOC727677^4^                                       n.a.                          AS              Apot           Kraus 2008
  T5189                                    16      CxCa      8q24.21    LOC727677                                         n.a.                          AS              Apot        
  T6697                                    18      CxCa      8q24.21    LOC727677                                        exon 6                          S              Apot        
  T3706                                    16      CxCa      13q22.1     BG182794        133.369                        intron 1                         S              Apot           Kraus 2008
  D3772                                    18      CxCa      13q22.1     BG182794                                       intron 1                         S              Apot           Kraus 2008
  D3632                                    45      CxCa      13q22.1     BG182794                                        exon 2                          S              Apot           Kraus 2008
  T4046                                    16      CxCa      13q22.1     BG182794                                        exon 2                          S              Apot        
  T182e                                    16      CxCa      15q22.1       LIPC          136.898                         exon 5                          S              Apot        
  T1907                                    16      CxCa      15q22.1       LIPC                                          exon 9                          S              Apot        
  T2723                                    18      CxCa      17q23.1      TMEM49         133.087                        exon 12                          S              Apot        
  T3231                                    18      CxCa      17q23.1      TMEM49                                        exon 12                          S              Apot        
  T30                                      18      CxCa      17q23.1    TMEM49^5^                                        exon 2                        n.s.             Apot          Ziegert 2003
  T24                                      18      CxCa      17q23.1    TMEM49^5^                                      exon 3^2^                        AS              Dips          Ziegert 2003
  107                                      16      CxCa      17q23.1    TMEM49^6^                                      exon 12^2^                      n.s.       Restriction PCR     Thorland 2003
  200229                                   16      CIN2      17q23.1    TMEM49^5^                                         n.s.                         n.s.             Dips          Matovina 2009

n.s.: not specified; n.a.: not applicable, because fusion transcript is in antisense orientation; ^†^integration sites without reference result from this work.

Two fusion transcripts were found in T2107; ^2^refers to sequenced integration sites; ^3^TP73L alias TP63; ^4^ *sweeker* in Kraus 2008 is no longer listed in any database; ^5^VMP1 alias TMEM49; ^6^DKFZP566I133 alias TMEM49.

Moreover, the genes *NT_008046.7*, *LOC727677*, *BG182794* and *TMEM49* are of particular note because at least two tumors harbour identical viral cellular fusion transcripts with respect to the viral donor and acceptor splice sites used.

Discussion {#s3}
==========

HPV integration into the host genome is likely to be a very frequent event but cannot be readily detected if integration occurs in a single cell without subsequent clonal selection pressure. In most cervical cancers there is only one transcriptionally active HPV integration site. There is evidence that these integration sites represent early clonal events which have provided a selective advantage for the expansion of the neoplasm. Because of their contribution to the carcinogenic process elucidation of these particular integration events are pertinent for understanding HPV-induced carcinogenesis.

Viral-cellular fusion transcripts are molecular markers for transcriptionally active integration sites and can be detected by a 3̀RACE protocol (the APOT assay) which allows PCR amplification for subsequent sequence analysis. In this study we have identified viral-cellular fusion transcripts in 47 cervical carcinomas. With one exception the fusion transcripts comprise cellular sequences of either known or predicted genes. This is in line with the results of our previous analysis and suggests that integration occurs mostly in transcriptionally active regions [@pone.0039632-Kraus1]. Moreover, in agreement with the literature 66% of the integration events were either within (34%) or adjacent to a fragile site (32%) [@pone.0039632-Koopman1], [@pone.0039632-Thorland1], [@pone.0039632-Ziegert1], [@pone.0039632-Kraus1]. Also integration of HPV DNA near miRNAs is evident. miRNAs are associated with the regulation of important processes such as development, proliferation, differentiation and apoptosis [@pone.0039632-Iorio1] and they are often deregulated in cancer cells [@pone.0039632-Iorio1], [@pone.0039632-Calin1]. Of the 75 miRNAs in the neighborhood of integration sites 19 have already been associated with cancer ([figure 1](#pone-0039632-g001){ref-type="fig"}). Of these miR-34a, miR-191, miR-28, miR-944, miR-31, miR-7-2, miR-9-3, miR-497, miR-195, miR-301a, miR-21, miR-181c, miR-27a, miR-99a and miR-let7c are expressed in cervical cancer cells [@pone.0039632-Lee1], [@pone.0039632-Lui1], [@pone.0039632-Cheng1], [@pone.0039632-Martinez1], [@pone.0039632-Volinia1], [@pone.0039632-Wang1]; whereas miR-34a, miR-21, miR-191, miR-9-3, miR-181d, miR-23a, miR-24-2, miR-99a and miR-125b2 are reported to be involved in other tumor entities [@pone.0039632-Volinia1], [@pone.0039632-Chang1], [@pone.0039632-Cho1], [@pone.0039632-Ueda1].

Of note is that for a substantial number of fusion transcripts (11/47) the viral sequences are spliced in sense orientation to cellular exons of known genes. Disruption of a gene by HPV integration, even if this occurs within intron sequences, is likely to have an impact on gene expression and in rare instances was shown to have contributed to a complete loss of gene function [@pone.0039632-Reuter1], [@pone.0039632-Schmitz1].

An important finding of this study is that it provides further support for a clustering of HPV integration sites in chromosomal hotspot regions. Of the 121 tumors analysed (including the data by Kraus et al., 2008) 22% of the viral-cellular fusion transcripts were assigned to one of five hotspots ([figure 1](#pone-0039632-g001){ref-type="fig"}). The hotspots range in size from 150 kb to 995 kb and contain up to 8 integration sites. Moreover, by including further published data 9 genes were found to be affected at least twice by HPV integration, four of these genes are located within the hotspots of the cytogenetic bands 3q28, 8q24.21 and 13q22.1 ([table 2](#pone-0039632-t002){ref-type="table"}). This observation is of particular interest because it suggests that integration is not only associated with transcriptionally active regions and nearby fragile sites. Especially since in some tumors even identical viral-cellular fusion transcripts with respect to viral-cellular splicing were found ([table 2](#pone-0039632-t002){ref-type="table"}). However, sequencing of the integration sites in case *TMEM49* had shown that the breakpoints of the two respective tumors are about 17 kb apart. Moreover, both integration sites showed no homology between the viral and cellular sequences [@pone.0039632-Schmitz1]. DNA recombination involving large stretches of homology at the integration site can at least be ruled out for *TMEM49*. Intriguingly sequence alignment of the genes listed in [Table 2](#pone-0039632-t002){ref-type="table"} has revealed several regions with high homology to the HPV16 genome. The most common region of high homology is between the viral gene E5 and L2 (nucleotides positions 4100 to 4240). Six of the 9 genes affected at least twice by HPV integration show a minimum of 80% homology in stretches of up to 34 nucleotides ([Sequences S1](#pone.0039632.s001){ref-type="supplementary-material"}). Moreover, each of the 9 genes show further homologies with other parts of the viral genome. Exemplarily the positions of the homologous regions of the adjoining genes *LEPREL1* and *TP63* with the HPV16 genome are depicted in [figure 2](#pone-0039632-g002){ref-type="fig"}. We speculate that these regions may be involved in the integration process. It is envisaged that the viral genome is tethered to chromatin by Brd4 which plays a key role in chromosomal functional events such as transcription, DNA replication, repair and recombination [@pone.0039632-You1], [@pone.0039632-Dey1]. The homologous stretches of DNA may then allow annealing of partially dissociated strands and thereby contribute to the recombination event. Sequence homology at the integration site itself need not be a prerequisite. Beyond this highly speculative scenario it is also interesting to note that all of the genes involved are cancer associated genes to varying degrees. If functionally impaired, they may have played a role in the clonal selection process. For the predicted genes *chr2.3.305.a* (N-SCAN), *NT_008046.7*, *LOC727677* (alias sweeker) and *BG182794* no functional data are available. However, *LRP1B* belongs to the low density lipoprotein receptor gene family and plays a role in the process of receptor-mediated endocytosis. A homozygous loss of *LRP1B* in several cervical tumors was found using array-based comparative genomic hybridization analysis [@pone.0039632-Choi1]. Also in other tumor entities like thyroid cancer [@pone.0039632-Prazeres1], gastric cancer [@pone.0039632-Lu1], lung cancer [@pone.0039632-Liu1], [@pone.0039632-Nagayama1], [@pone.0039632-Ding1], [@pone.0039632-Kohno1] and oral cancers [@pone.0039632-Sonoda1], [@pone.0039632-Nakagawa1] silencing or loss of *LRP1B* was observed. In functional terms *LRP1B* is able to inhibit cell migration [@pone.0039632-Li1] and its loss may thus be relevant for invasion and metastasis. The second gene, *LEPREL1*, encodes a protein involved in collagen biosynthesis, folding and assembly. Thus far this gene was not associated with cervical cancer but it was observed to be silenced breast cancer cell lines and in 26% of breast cancers analysed [@pone.0039632-Shah1]. Two further genes are *TP63* and *LIPC*. *TP63*, a member of the p53 protein family, is another gene affected by integration. It acts as a tumor suppressor protein and aberrant expression was noted for several cancer entities including cervical cancer [@pone.0039632-Vasilescu1], [@pone.0039632-Nishi1]. *LIPC* is a cytoplasmic protein mainly expressed in the liver. It is involved in the lipidprotein metabolism and catalyzes hydrolysis of phospholipids, mono-, di- and triglycerides and acyl-CoA thioesters [@pone.0039632-SantamarinaFojo1]. A direct link to carcinogenesis is not readily apparent but in a recent study a complete lack of expression was observed in 18% of cervical carcinomas. By contrast all normal cervical epithelia, metaplasia and CIN examined expressed LIPC [@pone.0039632-Schmitz1]. The most frequently affected gene, being disrupted 6 times, is *TMEM49* (transmembrane protein 49), also known as *VMP1* (vacuole membrane protein 1) located on chromosome 17q23.1. It encodes a plasma membrane protein which is an essential component of initial cell-cell contacts and tight junction formations [@pone.0039632-Sauermann1]. Reduced expression of *TMEM49* was found for invasive breast cancer cell lines and in kidney cancer metastasis [@pone.0039632-Sauermann1]. *TMEM49* also appears to be particularly prominent in terms of deregulation of nearby miRNAs. miR21 is located only 676 bp downstream of this gene and may as a consequence of HPV integration be either up or down-regulated. Association of this miRNA has been reported for the caspase cascade [@pone.0039632-Chan1] and it can target BTG2, a gene with antiproliferative properties [@pone.0039632-Liu2]. Thus far miR21 was shown to be upregulated in multiple cancers such as breast, lung, colon, pancreas, prostate, stomach, ovary and uterus [@pone.0039632-Volinia1], [@pone.0039632-Cho1], [@pone.0039632-Ueda1].

![Sequence homologies between the HPV16 genome and the two adjoining genes *TP63* and *LEPREL1*.\
Three homologous stretches of up to 50 nucleotides are shown. The number of exact nucleotide matches is given in brackets (see also [Sequences S1](#pone.0039632.s001){ref-type="supplementary-material"}). The DNA loop between the two homologies located on *LEPREL1* comprises 102.689 nucleotides; the second loop 269.968 nucleotides. Grey dots refer to the approximate location of the corresponding viral-cellular fusion transcripts detected in tumors D3829, T2107 and T4335 (from left to right).](pone.0039632.g002){#pone-0039632-g002}

By characterising an increasing number of transcriptionally active HPV integration sites it has become evident that integration is not an entirely random event but also involves preferred chromosomal sites. In individual cases this may impair gene function and promote malignant progression. Presently we can only speculate on the mechanisms that contribute to this phenomenon.

Materials and Methods {#s4}
=====================

Clinical Samples {#s4a}
----------------

In this study, 69 HPV16 and 18 HPV18 positive biopsies from cervical carcinoma patients were screened for HPV integration by the APOT assay. For HPV genotyping a Taqman based multiplex real-time PCR assay was used [@pone.0039632-Schmitz2]. All biopsies were taken from patients treated at the Department of Gynecology of Friedrich-Schiller-Universität, Jena, Germany between 1995 and 2008. All tumors were histopathologically classified as squamous cell carcinomas.

Nucleic Acid Isolation {#s4b}
----------------------

Total RNA was isolated using the NucleoSpin RNA II Kit (Macherey-Nagel, Düren, Germany) according to the protocol for RNA isolation from tissues. Samples were homogenized by the use of injection needles with a diameter of 0,55 mm. DNA was removed in all samples by DNase treatment for 15 min (RT). DNase was supplied with the NucleoSpin RNA II Kit. Total RNA was eluted in 60 µl RNase-free water and stored at −80°C for further analysis.

Reverse Transcription {#s4c}
---------------------

Total RNA (300--500 ng) was reverse-transcribed using 200 units of Superscript II reverse transcriptase (Invitrogen, Carlsbad, California, USA) and an oligo(dT) primer coupled to a linker sequence (5′-AAG CAG TGG TAT CAA CGC AGA GTA CT~(30)~VN-3′), referred to as CDS-Primer (Clontech, Heidelberg, Germany). The reaction was incubated for 70 min at 42°C in a final volume of 20 µl according to the protocol of the Superscript II Kit. 40 units of RNaseOUT (Invitrogen, Carlsbad, California, USA) were added to inhibit RNase activity.

Amplification of Papillomavirus Oncogene Transcript (APOT) Assay {#s4d}
----------------------------------------------------------------

HPV-derived fusion transcripts were amplified using the APOT assay [@pone.0039632-Klaes1]. It is based on a 3′-rapid amplification of cDNA ends (RACE) performed in a nested PCR format. HPV E7 primers are used as forward primers (HPV16: first primer: CGGACA GAG CCC ATT ACA AT, second primer: CCTTTT GTT GCA AGT GTG ACT CTA CG; HPV18: first primer: TAG AAA GCT CAG CAG ACG ACC, second primer: ACGACC TTC GAG CAT TCC AGC AG) and an adapter primer complementary to the linker sequence in the CDS primer as first reverse primer and the CDS Primer as second nested primer.

The APOT assay was done as previously described [@pone.0039632-Klaes1] with slight modifications with regard to the primer used. The reverse primer for the first PCR comprises the sequence 5′-AAG CAG TGG TAA CAA CGC A-3′, the nested PCR primer the sequence 5′-AAG CAG TGG TAA CAA CGC AGA GTA CT-3′. The reaction mixture, containing 20 mM Tris-HCl, 50 mM KCl, 1.5 mM MgCl~2~, 200 µM dNTPs, 250 nM primer each and 0.75 units recombinant Taq Polymerase (Invitrogen, Carlsbad, California, USA), was subjected to an initial denaturation step for 5 min at 94°C, followed by 30 cycles of denaturation at 94°C for 30 sec, primer annealing for 30 sec and elongation at 72°C for 2 min. For HPV16, annealing temperatures of 61°C and 66°C for the first and second PCR, respectively, were used; for HPV18, 61°C and 68°C. The reaction was terminated by a final elongation step at 72°C for 6 min. Two microliters of the first PCR were used as template for the nested PCR step. Both reactions were performed in a volume of 25 microliters. The amplification products were visualized by 1% agarose gel electrophoresis. Products which differ in their size from the major viral transcript (E6\*1--E7--E1~v~E4--E5) are indicative for viral-cellular fusion transcripts. The APOT assay has several limitations. A tumor in which the integrated HPV genome is transcriptionally silent will not reveal the characteristic viral-cellular fusion transcript and will therefore be scored as negative for integration. Moreover, the assay may not detect viral-cellular fusion transcripts in the presence of an excess of transcripts derived from episomal HPV genomes. Finally, a tumor in which the integrated HPV genome persists in form of a concatemer the viral transcripts may not comprise cellular sequences and therefore cannot be differentiated from episome-derived transcripts. Overall the assay underestimates the number of tumors with integrated HPV DNA.

Sequence Analyses {#s4e}
-----------------

Viral-cellular fusion transcripts were excised from the gel and extracted using the Zymoclean Gel DNA Recovery Kit (AnalytikJena, Jena, Germany). The isolated products were sequenced (Seqlab, Göttingen, Germany) and the integration locus was determined by database alignments using National Centre for Biotechnology Information (NCBI) human megaBlast tool and the University of California, Santa Cruz (USCS) genome browser.

PCR {#s4f}
---

For selected samples (n = 13) the existence of viral-cellular fusion transcripts was verified by PCR using viral and cellular integration specific primers. PCR amplification was performed in a final volume of 25 microliters containing 20 mM Tris-HCl, 3 mM MgCl~2~, 50 mM KCl, 200 µM dNTPs, primer 400 nM each and 1.5U Platinum Taq DNA Polymerase (Invitrogen, Carlsbad, California, USA). PCR reactions were performed with an initial denaturation step at 94°C for 10 min, followed by 45 cycles of denaturation at 94°C for 15 sec, annealing at 58--60°C (depending on the primer pair used) for 20 sec and elongation at 72°C for 30 sec.

In Silico Analyses {#s4g}
------------------

For chromosomal mapping of the viral-cellular fusion transcripts and to relate HPV integration to fragile sites and miRNAs, the University of California, Santa Cruz (UCSC) genome browser (hg19) and the Map Viewer (Build 37.3) of the National Centre for Biotechnology Information (NCBI) were used. All known miRNA sequences are listed in the miRNA registry "miRBase" (<http://www.mirbase.org/>) with 1527 records (release 18) for homo sapiens.

Investigation of Integration Loci Frequency {#s4h}
-------------------------------------------

To determine the frequency of HPV integration in specific genes and hotspots, data published by Dall 2008, Ferber 2003, Kraus 2008, Matovina 2009, Peter 2006, Thorland 2003, Wentzensen 2002 and 2004 and Ziegert 2003 [@pone.0039632-Wentzensen1], [@pone.0039632-Ferber1], [@pone.0039632-Peter2], [@pone.0039632-Thorland1], [@pone.0039632-Ziegert1], [@pone.0039632-Kraus1], [@pone.0039632-Dall1], [@pone.0039632-Matovina1], [@pone.0039632-Wentzensen2] were included.
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